Chlorine in PDB 6ut0: Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Protein crystallography data
The structure of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer, PDB code: 6ut0
was solved by
G.P.Vigers,
D.J.Smith,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
28.32 /
1.94
|
Space group
|
P 1 21 1
|
Cell size a, b, c (Å), α, β, γ (°)
|
74.918,
61.800,
76.050,
90.00,
111.37,
90.00
|
R / Rfree (%)
|
17.5 /
22.2
|
Other elements in 6ut0:
The structure of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer also contains other interesting chemical elements:
Chlorine Binding Sites:
The binding sites of Chlorine atom in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
(pdb code 6ut0). This binding sites where shown within
5.0 Angstroms radius around Chlorine atom.
In total 4 binding sites of Chlorine where determined in the
Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer, PDB code: 6ut0:
Jump to Chlorine binding site number:
1;
2;
3;
4;
Chlorine binding site 1 out
of 4 in 6ut0
Go back to
Chlorine Binding Sites List in 6ut0
Chlorine binding site 1 out
of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 1 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Cl203
b:36.9
occ:1.00
|
CL1
|
A:M1X203
|
0.0
|
36.9
|
1.0
|
C29
|
A:M1X203
|
1.7
|
26.9
|
1.0
|
C28
|
A:M1X203
|
2.6
|
25.1
|
1.0
|
HD1
|
A:TYR96
|
2.8
|
16.5
|
1.0
|
C25
|
A:M1X203
|
2.8
|
24.9
|
1.0
|
N9
|
A:M1X203
|
2.8
|
21.9
|
1.0
|
HE2
|
A:MET72
|
3.1
|
22.5
|
1.0
|
C10
|
A:M1X203
|
3.1
|
19.1
|
1.0
|
C20
|
A:M1X203
|
3.2
|
23.6
|
1.0
|
HG12
|
A:VAL9
|
3.3
|
15.2
|
1.0
|
HE1
|
A:TYR96
|
3.4
|
16.5
|
1.0
|
HE3
|
A:MET72
|
3.5
|
22.5
|
1.0
|
CD1
|
A:TYR96
|
3.6
|
16.6
|
1.0
|
HB
|
A:VAL9
|
3.6
|
15.0
|
1.0
|
CE
|
A:MET72
|
3.7
|
22.2
|
1.0
|
C2
|
A:M1X203
|
3.7
|
20.1
|
1.0
|
HG22
|
A:THR58
|
3.7
|
14.9
|
1.0
|
HG11
|
A:VAL9
|
3.8
|
15.2
|
1.0
|
CE1
|
A:TYR96
|
3.8
|
16.0
|
1.0
|
HE1
|
A:MET72
|
3.9
|
22.5
|
1.0
|
CG1
|
A:VAL9
|
3.9
|
15.3
|
1.0
|
C8
|
A:M1X203
|
4.0
|
21.4
|
1.0
|
C7
|
A:M1X203
|
4.0
|
19.2
|
1.0
|
C27
|
A:M1X203
|
4.0
|
24.6
|
1.0
|
C1
|
A:M1X203
|
4.1
|
18.7
|
1.0
|
C24
|
A:M1X203
|
4.1
|
26.9
|
1.0
|
N41
|
A:M1X203
|
4.2
|
15.6
|
1.0
|
CB
|
A:VAL9
|
4.2
|
14.9
|
1.0
|
HB2
|
A:GLN99
|
4.5
|
18.7
|
1.0
|
C26
|
A:M1X203
|
4.5
|
25.1
|
1.0
|
N3
|
A:M1X203
|
4.5
|
19.2
|
1.0
|
HG3
|
A:MET72
|
4.5
|
23.0
|
1.0
|
HA
|
A:TYR96
|
4.5
|
17.5
|
1.0
|
C21
|
A:M1X203
|
4.6
|
24.5
|
1.0
|
HG22
|
A:VAL9
|
4.7
|
14.9
|
1.0
|
CG2
|
A:THR58
|
4.7
|
15.2
|
1.0
|
HB3
|
A:TYR96
|
4.8
|
17.0
|
1.0
|
CG
|
A:TYR96
|
4.8
|
16.1
|
1.0
|
HB3
|
A:GLN99
|
4.8
|
18.7
|
1.0
|
HG13
|
A:VAL9
|
4.8
|
15.2
|
1.0
|
HG1
|
A:THR58
|
4.8
|
14.5
|
0.0
|
C40
|
A:M1X203
|
4.9
|
16.4
|
1.0
|
HG3
|
A:GLN99
|
5.0
|
19.6
|
1.0
|
|
Chlorine binding site 2 out
of 4 in 6ut0
Go back to
Chlorine Binding Sites List in 6ut0
Chlorine binding site 2 out
of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 2 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:Cl203
b:25.0
occ:1.00
|
CL1
|
B:M1X203
|
0.0
|
25.0
|
1.0
|
C29
|
B:M1X203
|
1.7
|
17.8
|
1.0
|
C28
|
B:M1X203
|
2.6
|
18.3
|
1.0
|
HD1
|
B:TYR96
|
2.8
|
16.4
|
1.0
|
C25
|
B:M1X203
|
2.8
|
16.4
|
1.0
|
N9
|
B:M1X203
|
2.9
|
15.4
|
1.0
|
HE2
|
B:MET72
|
3.0
|
20.3
|
1.0
|
HE1
|
B:TYR96
|
3.2
|
16.6
|
1.0
|
HG12
|
B:VAL9
|
3.3
|
12.5
|
1.0
|
C10
|
B:M1X203
|
3.3
|
15.0
|
1.0
|
C20
|
B:M1X203
|
3.3
|
16.4
|
1.0
|
CD1
|
B:TYR96
|
3.5
|
16.3
|
1.0
|
HB
|
B:VAL9
|
3.5
|
12.5
|
1.0
|
HE3
|
B:MET72
|
3.5
|
20.3
|
1.0
|
CE
|
B:MET72
|
3.7
|
20.1
|
1.0
|
HG22
|
B:THR58
|
3.7
|
13.8
|
1.0
|
CE1
|
B:TYR96
|
3.7
|
16.4
|
1.0
|
HG11
|
B:VAL9
|
3.9
|
12.5
|
1.0
|
C2
|
B:M1X203
|
3.9
|
14.2
|
1.0
|
CG1
|
B:VAL9
|
3.9
|
12.6
|
1.0
|
C27
|
B:M1X203
|
4.0
|
16.9
|
1.0
|
C8
|
B:M1X203
|
4.0
|
13.7
|
1.0
|
N41
|
B:M1X203
|
4.0
|
13.4
|
1.0
|
C7
|
B:M1X203
|
4.0
|
15.4
|
1.0
|
HE1
|
B:MET72
|
4.1
|
20.3
|
1.0
|
C24
|
B:M1X203
|
4.1
|
15.1
|
1.0
|
C1
|
B:M1X203
|
4.2
|
14.6
|
1.0
|
CB
|
B:VAL9
|
4.2
|
12.3
|
1.0
|
HG3
|
B:MET72
|
4.3
|
20.3
|
1.0
|
C26
|
B:M1X203
|
4.5
|
16.1
|
1.0
|
HG22
|
B:VAL9
|
4.6
|
12.5
|
1.0
|
HB2
|
B:GLN99
|
4.6
|
14.6
|
1.0
|
CG2
|
B:THR58
|
4.6
|
14.3
|
1.0
|
HG1
|
B:THR58
|
4.6
|
14.2
|
0.0
|
HA
|
B:TYR96
|
4.7
|
16.8
|
1.0
|
C21
|
B:M1X203
|
4.7
|
16.6
|
1.0
|
N3
|
B:M1X203
|
4.7
|
15.6
|
1.0
|
CG
|
B:TYR96
|
4.7
|
16.4
|
1.0
|
HG13
|
B:VAL9
|
4.8
|
12.5
|
1.0
|
HB3
|
B:TYR96
|
4.8
|
16.8
|
1.0
|
C40
|
B:M1X203
|
4.9
|
13.8
|
1.0
|
HB3
|
B:GLN99
|
4.9
|
14.6
|
1.0
|
CG2
|
B:VAL9
|
5.0
|
12.5
|
1.0
|
HG21
|
B:THR58
|
5.0
|
13.8
|
1.0
|
|
Chlorine binding site 3 out
of 4 in 6ut0
Go back to
Chlorine Binding Sites List in 6ut0
Chlorine binding site 3 out
of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 3 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
C:Cl203
b:31.9
occ:1.00
|
CL1
|
C:M1X203
|
0.0
|
31.9
|
1.0
|
C29
|
C:M1X203
|
1.7
|
19.9
|
1.0
|
C28
|
C:M1X203
|
2.6
|
17.6
|
1.0
|
C25
|
C:M1X203
|
2.8
|
18.3
|
1.0
|
HD1
|
C:TYR96
|
2.8
|
13.0
|
1.0
|
N9
|
C:M1X203
|
2.8
|
16.4
|
1.0
|
HE2
|
C:MET72
|
3.0
|
19.5
|
1.0
|
C10
|
C:M1X203
|
3.0
|
15.0
|
1.0
|
HG12
|
C:VAL9
|
3.2
|
13.5
|
1.0
|
C20
|
C:M1X203
|
3.2
|
17.7
|
1.0
|
HE1
|
C:TYR96
|
3.3
|
13.1
|
1.0
|
HG11
|
C:VAL9
|
3.5
|
13.5
|
1.0
|
HG22
|
C:THR58
|
3.6
|
12.7
|
1.0
|
CD1
|
C:TYR96
|
3.6
|
13.2
|
1.0
|
C2
|
C:M1X203
|
3.7
|
15.0
|
1.0
|
HE3
|
C:MET72
|
3.7
|
19.5
|
1.0
|
CE
|
C:MET72
|
3.7
|
19.9
|
1.0
|
CG1
|
C:VAL9
|
3.7
|
13.9
|
1.0
|
HB
|
C:VAL9
|
3.7
|
12.7
|
1.0
|
CE1
|
C:TYR96
|
3.8
|
12.8
|
1.0
|
HE1
|
C:MET72
|
3.9
|
19.5
|
1.0
|
C7
|
C:M1X203
|
3.9
|
14.9
|
1.0
|
C27
|
C:M1X203
|
3.9
|
16.0
|
1.0
|
C8
|
C:M1X203
|
4.0
|
15.8
|
1.0
|
C24
|
C:M1X203
|
4.0
|
17.3
|
1.0
|
C1
|
C:M1X203
|
4.1
|
15.9
|
1.0
|
N41
|
C:M1X203
|
4.1
|
15.0
|
1.0
|
CB
|
C:VAL9
|
4.3
|
12.8
|
1.0
|
HB2
|
C:GLN99
|
4.4
|
14.7
|
1.0
|
C26
|
C:M1X203
|
4.4
|
17.4
|
1.0
|
HA
|
C:TYR96
|
4.5
|
13.7
|
1.0
|
CG2
|
C:THR58
|
4.5
|
12.6
|
1.0
|
N3
|
C:M1X203
|
4.5
|
14.7
|
1.0
|
HG13
|
C:VAL9
|
4.6
|
13.5
|
1.0
|
C21
|
C:M1X203
|
4.6
|
16.7
|
1.0
|
HG3
|
C:MET72
|
4.7
|
17.5
|
1.0
|
HG22
|
C:VAL9
|
4.7
|
12.1
|
1.0
|
HG21
|
C:THR58
|
4.8
|
12.7
|
1.0
|
HB3
|
C:GLN99
|
4.8
|
14.7
|
1.0
|
CG
|
C:TYR96
|
4.8
|
12.5
|
1.0
|
HG3
|
C:GLN99
|
4.8
|
15.3
|
1.0
|
HG1
|
C:THR58
|
4.9
|
12.8
|
0.0
|
HB3
|
C:TYR96
|
4.9
|
13.2
|
1.0
|
C40
|
C:M1X203
|
4.9
|
14.0
|
1.0
|
HG23
|
C:THR58
|
4.9
|
12.7
|
1.0
|
|
Chlorine binding site 4 out
of 4 in 6ut0
Go back to
Chlorine Binding Sites List in 6ut0
Chlorine binding site 4 out
of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 4 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
D:Cl203
b:30.5
occ:1.00
|
CL1
|
D:M1X203
|
0.0
|
30.5
|
1.0
|
C29
|
D:M1X203
|
1.7
|
19.9
|
1.0
|
C28
|
D:M1X203
|
2.6
|
19.0
|
1.0
|
HD1
|
D:TYR96
|
2.6
|
16.6
|
1.0
|
C25
|
D:M1X203
|
2.8
|
19.4
|
1.0
|
HE3
|
D:MET72
|
2.8
|
21.9
|
1.0
|
N9
|
D:M1X203
|
3.0
|
17.1
|
1.0
|
HG12
|
D:VAL9
|
3.1
|
16.1
|
1.0
|
HE1
|
D:TYR96
|
3.2
|
16.9
|
1.0
|
C10
|
D:M1X203
|
3.2
|
15.4
|
1.0
|
C20
|
D:M1X203
|
3.3
|
17.1
|
1.0
|
CD1
|
D:TYR96
|
3.4
|
16.0
|
1.0
|
HB
|
D:VAL9
|
3.4
|
16.1
|
1.0
|
HE2
|
D:MET72
|
3.5
|
21.9
|
1.0
|
CE
|
D:MET72
|
3.5
|
21.8
|
1.0
|
HG11
|
D:VAL9
|
3.6
|
16.1
|
1.0
|
CE1
|
D:TYR96
|
3.7
|
17.2
|
1.0
|
CG1
|
D:VAL9
|
3.7
|
15.9
|
1.0
|
HG22
|
D:THR58
|
3.8
|
15.3
|
1.0
|
C2
|
D:M1X203
|
3.8
|
17.1
|
1.0
|
HE1
|
D:MET72
|
3.8
|
21.9
|
1.0
|
C27
|
D:M1X203
|
4.0
|
20.5
|
1.0
|
C7
|
D:M1X203
|
4.0
|
18.0
|
1.0
|
C24
|
D:M1X203
|
4.0
|
18.9
|
1.0
|
N41
|
D:M1X203
|
4.1
|
17.2
|
1.0
|
CB
|
D:VAL9
|
4.1
|
16.5
|
1.0
|
C8
|
D:M1X203
|
4.2
|
17.6
|
1.0
|
C1
|
D:M1X203
|
4.2
|
17.1
|
1.0
|
HG22
|
D:VAL9
|
4.4
|
16.3
|
1.0
|
HG3
|
D:MET72
|
4.5
|
18.9
|
1.0
|
HA
|
D:TYR96
|
4.5
|
16.6
|
1.0
|
C26
|
D:M1X203
|
4.5
|
18.2
|
1.0
|
HB2
|
D:GLN99
|
4.6
|
16.8
|
1.0
|
HG13
|
D:VAL9
|
4.6
|
16.1
|
1.0
|
N3
|
D:M1X203
|
4.6
|
16.2
|
1.0
|
CG
|
D:TYR96
|
4.6
|
16.9
|
1.0
|
C21
|
D:M1X203
|
4.7
|
17.7
|
1.0
|
HB3
|
D:TYR96
|
4.7
|
16.8
|
1.0
|
CG2
|
D:THR58
|
4.8
|
15.3
|
1.0
|
HG1
|
D:THR58
|
4.8
|
15.5
|
0.0
|
CG2
|
D:VAL9
|
4.8
|
16.3
|
1.0
|
C40
|
D:M1X203
|
4.8
|
20.7
|
1.0
|
HB3
|
D:GLN99
|
4.9
|
16.8
|
1.0
|
|
Reference:
J.B.Fell,
J.P.Fischer,
B.R.Baer,
J.F.Blake,
K.Bouhana,
D.M.Briere,
K.D.Brown,
L.E.Burgess,
A.C.Burns,
M.R.Burkard,
H.Chiang,
M.J.Chicarelli,
A.W.Cook,
J.J.Gaudino,
J.Hallin,
L.Hanson,
D.P.Hartley,
E.J.Hicken,
G.P.Hingorani,
R.J.Hinklin,
M.J.Mejia,
P.Olson,
J.N.Otten,
S.P.Rhodes,
M.E.Rodriguez,
P.Savechenkov,
D.J.Smith,
N.Sudhakar,
F.X.Sullivan,
T.P.Tang,
G.P.Vigers,
L.Wollenberg,
J.G.Christensen,
M.A.Marx.
Identification of the Clinical Development CANDIDATEMRTX849, A Covalent KRASG12CINHIBITOR For the Treatment of Cancer. J.Med.Chem. 2020.
ISSN: ISSN 0022-2623
PubMed: 32250617
DOI: 10.1021/ACS.JMEDCHEM.9B02052
Page generated: Mon Jul 29 15:59:38 2024
|